Abstract| Volume 15, ISSUE 7, SUPPLEMENT , S180, September 2009

Curcumin Exerts Synergistic Effects With ACE Inhibitor During Systolic Function Restoration After Myocardial Infarction in Rats

      Purpose: We found that curcumin, a p300 histone acetyltransferase inhibitor, prevents deterioration of the systolic function in rat heart failure models in vivo. To clinically apply this novel therapy to humans, it should be clarified whether or not Cur exhibits additional effects on conventional HF therapy involving angiotensin-converting enzyme inhibitors (ACEI). Methods: Rats were subjected to a sham operation or MI. One week later, 32 rats were randomly assigned to solvents (control), enalapril (ACEI, 10 mg/kg/day) alone, curcumin (50 mg/kg/day) alone, or curcumin plus enalapril for 6 weeks. Results: ACEI, but not curcumin treatment, decreased the blood pressure in post-MI rats. After treatment, LVFS was significantly (p<0.05) higher in the ACEI (29%) and curcumin (29%) groups than in the vehicle group (22%). Notably, LVFS significantly (p<0.05) increased on ACEI/Cur combination therapy (35%) compared with therapy involving either ACEI or curcumin alone. The LV wall thickness and cardiomyocyte diameter were significantly smaller in the ACEI/curcumin than the ACEI group. Moreover, perivascular fibrosis was significantly reduced in the ACEI and curcumin groups compared with the vehicle group. This reduction was further augmented by the ACEI/curcumin combination therapy. Conclusions: Curcumin, restores the post-MI LV systolic function in rats without affecting the blood pressure. This natural non-toxic dietary compound in addition to ACEI exerts beneficial effects on LV systolic function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect